Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07359209
NA

Berberine Improving Cognitive Impairments in Schizophrenia

Sponsor: Tianjin Anding Hospital

View on ClinicalTrials.gov

Summary

The study was a 12-week, randomized, double-blind, placebo-controlled trial. Berberine (300 mg, three times a day) has been used as an auxiliary treatment on the basis of stable antipsychotic treatment. All participants were randomly divided into two groups.Any stable antipsychotic + berberine(BBR) or any stable antipsychotic +placebo. Positive and Negative Syndrome Scale (PANSS) has been used for psychiatric symptoms. MATRICS Consensus Cognitive Battery(MCCB)has been used for cognitive symptoms. The treatment Emergent Symptom Scale(TESS) has been used for evaluate adverse effects. Plasma Metabolomics, Inflammatory Factors, BDNF, fecal Macrogene Sequencing, and fecal Metabolomics were obtained at 0, 4,8 ,12weeks.

Official title: Study on the Mechanism s of Berberine Improving Cognitive Impairments in Schizophrenia Based on "Gut m Icrobiota-gut-brain"Axis

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-07-21

Completion Date

2028-07-30

Last Updated

2026-01-22

Healthy Volunteers

No

Interventions

DRUG

Berberine

Berberine 300mg#three times a day# plus any stable antipsychotic drug

DRUG

Placebo

The placebo were matched to Berberine in shape, smell and colour and tablets were sealed in identical bottles

Locations (1)

Tianjin Anding Hospital

Tianjin, China